Authors
Latest:
Clinical Manifestations of Acute, Chronic Graft-vs-Host Disease With PTCy in Patients Receiving Allogeneic Hematopoietic Stem Cell TransplantationThis abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.
Latest:
Clinical Overview: Fecal Microbiota Transplantation vs Live Biotherapeutic Products for Management of Recurrent C Difficile InfectionAlthough antibiotics are the standard-of-care treatment for Clostridioides difficile infection, they can cause further microbiota changes that predispose patients to recurrence.
Latest:
Blood Glucose Monitoring in Diabetes Care: When Innovation is Hidden In Plain SightPharmacies have long embraced innovation and technology, with early adoption of telehealth and digital platforms.
Latest:
Breaking Silos: How Health Systems and Manufacturers Can Drive Progress TogetherVanderbilt Specialty Pharmacy and Takeda Oncology are reaching across silos and entering an innovative partnership to improve patient care across the entire medication journey.
Latest:
Developing the Missing Piece in Mental Health TreatmentIt is important that mental health professionals and providers look to newer approaches and methods to supplement the current standard of care.
Latest:
Equitable Representation in Triple-Negative Breast Cancer Clinical TrialsBlack women have higher rates of triple-negative breast cancer (TNBC) incidence and mortality than the general US population. Despite this, they are underrepresented in TNBC clinical trials.
Latest:
Immunotherapy Takes the Lead in Advanced Cutaneous MalignanciesHeidi Finnes, PharmD, BCOP, FHOPA, discusses the evolving landscape of treatment of cutaneous malignancies.
Latest:
Parenting and Pharmacy Residency: 4 Tips and Tricks for SuccessAlthough everyone’s residency looks different, it is important for mothers to assess childcare options, be transparent about their schedule, and take care of themselves.
Latest:
Removal of Phenylephrine From Nasal Decongestants Could Reshape OTC Cold RemediesIntranasal decongestants are preferred alternatives to oral phenylephrine for relief of nasal congestion.
Latest:
June 2023 Interactive Case StudiesCases highlight patients who have attention-deficity/hyperactivity disorder and diabetic peripheral nephropathy.
Latest:
Community Pharmacies Positioned to be the Epicenter of CareCommunity pharmacists have an essential role to play during this phase of the crisis that could further entrench them as the epicenter of care in the communities they serve.
Latest:
Overcoming Metallo-β-Lactamases: A Review of Cefepime-TaniborbactamCefepime-taniborbactam shows promise against resistant infections, but more studies are needed.
Latest:
More Options, More Questions: How Pharmacists Are Managing EGFR-Positive Non-Small Cell Lung CancerShelby Quinn, PharmD, BCOP shares insights about treatment using osimertinib in early lines.
Latest:
A 340B Compromise at Last? Draft Federal Legislation May Provide a Clear Path ForwardIn an ambitious effort to address the ongoing uncertainty within the 340B Program space, 6 senators released a draft discussion bill earlier this year titled the SUSTAIN Act.
Latest:
Antineoplastic Extravasation Prevention, ManagementExtravasation is defined as the inadvertent leakage of a vesicant from the vein into the surrounding tissue.
Latest:
A Pharmacist’s Guide to Medical Cannabis Interactions and Patient CareAs access becomes easier, pharmacists are more likely to encounter questions.
Latest:
Clinical Overview: Teprotumumab for Thyroid Eye DiseaseTeprotumumab is the first fully human IgG1 monoclonal antibody approved by the FDA for the treatment of thyroid eye disease at its source not just reducing the symptoms.
Latest:
Fostering Equity in Health Care Research: Eliminating Gender Bias With Decentralized Clinical Trials for WomenDecentralized clinical trials are emerging as a method by which to address gender bias in clinical research.
Latest:
Pharmacists Have a Significant Role in Chronic Kidney DiseaseThe Kidney Disease: Improving Global Outcomes guidelines can provide pharmacists with approaches to minimizing chronic kidney disease progression and complications.
Latest:
2030: The Beginning of a New Era in Health CareBy setting a standard for prescriptions that improves member access, outcomes, and experience, we will establish a path forward for every facet of health care.
Latest:
Case Studies in PharmacogenomicsThe potential to optimize medication efficacy and safety across diverse populations is garnering attention in various health care settings.
Latest:
Medication Compliance When Treating CKD is Crucial, UPMC Health Plan Expert SaysHelping patients adhere to their medications to manage their chronic kidney disease (CKD) and comorbidities is one of the key areas pharmacists should prioritize.
Latest:
From Inpatient to Outpatient: A Pharmacy-Led Evolution in Transplant CareErin Lexner, PharmD, BCPS, discussed her team’s experience transitioning to outpatient BEAM from inpatient CBV.
Latest:
Locking Prescription Vials Helps Keep Medicine Safe in Medication-assisted Treatment ProgramsFor patients with opioid use disorder, medication-assisted treatment programs are a clinically effective approach.
Latest:
The Term 'Bispecific Antibody' Is No Longer EnoughBispecific therapies require clearer terminology to improve safety and communication.
Latest:
Removing Mesna From Cyclophosphamide Cycles in VAdriaC-IE for Ewing SarcomaThis retrospective cohort study provides preliminary evidence for safe removal of mesna from VAdriaC cycles, as the incidence of hemorrhagic cystitis did not increase in patients with Ewing sarcoma who received cyclophosphamide without prophylactic mesna.
Latest:
The Power of Our Voice: Why Pharmacists Must Advocate for Our ProfessionAdvocacy ensures that policymakers understand the realities on the ground. If we fail to speak up, decisions about our profession will be made without our input—often by individuals who lack the expertise and perspective we bring to the table.
Latest:
Breaking New Ground: Emerging Therapies for Treatment of EGFR-Positive NSCLCA panelist discusses how emerging advancements in non–small cell lung cancer (NSCLC) treatment include the anticipated FDA approval of subcutaneous amivantamab, which would significantly reduce infusion-related reactions seen in the MARIPOSA trials while improving patient experience and reducing infusion center chair time, as well as promising antibody-drug conjugates like sacituzumab govitecan (Trodelvy) that may provide better first and second-line treatment options with potentially less toxicity than current standard regimens.
